Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or “Ecstasy”)
- 1 June 1995
- journal article
- review article
- Published by Springer Nature in Psychopharmacology
- Vol. 119 (3), 247-260
- https://doi.org/10.1007/bf02246288
Abstract
No abstract availableKeywords
This publication has 133 references indexed in Scilit:
- The Interactions of MK-801 with the Amphetamine Analogues d-Methamphetamine (d-METH), 3,4-Methylenedioxymethamphetamine (d-MDMA) or d-Fenfluramine (d-FEN): Neural Damage and Neural ProtectionAnnals of the New York Academy of Sciences, 1993
- Accidental ingestion of 'Ecstasy' (3,4-methylenedioxymethylamphetamine).Archives of Disease in Childhood, 1992
- Psychiatric illness associated with "ecstasy"The Lancet, 1991
- Chronic paranoid psychosis after misuse of MDMA.BMJ, 1991
- Acute inactivation of tryptophan hydroxylase by amphetamine analogs involves the oxidation of sulfhydryl sitesEuropean Journal of Pharmacology: Molecular Pharmacology, 1989
- Toxic effects of MDMA on central serotonergic neurons in the primate: importance of route and frequency of drug administrationBrain Research, 1988
- Incidence of Recreational Use of 3,4-Methylenedimethoxymethamphetamine (MDMA, Ecstasy) on an Undergraduate CampusNew England Journal of Medicine, 1987
- A Case of Mao Inhibitor/MDMA Interaction: Agony After EcstasyJournal of Toxicology: Clinical Toxicology, 1987
- 8-hydroxy-2-(di-n-propylamino)tetralin, 8-OH-DPAT, a potent and selective simplified ergot congener with central 5-HT-receptor stimulating activityJournal of Neural Transmission, 1982
- Amphetamine Toxicity in Aggregated MiceJournal of Pharmacy and Pharmacology, 1961